Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Polypharmacology in the treatment of Chagas disease.

Aguilera E, Alvarez G, Cerecetto H, Gonzalez M.

Curr Med Chem. 2018 Apr 9. doi: 10.2174/0929867325666180410101728. [Epub ahead of print]

PMID:
29637852
2.

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.

Aguilera E, Varela J, Serna E, Torres S, Yaluff G, Bilbao NV, Cerecetto H, Alvarez G, González M.

Mem Inst Oswaldo Cruz. 2018 Mar;113(3):153-160. doi: 10.1590/0074-02760170267.

3.

Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.

Duschak VG.

Recent Pat Antiinfect Drug Discov. 2016;11(2):74-173. doi: 10.2174/1574891X11666161024165304. Review.

PMID:
27784230
4.

Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease.

Beltran-Hortelano I, Perez-Silanes S, Galiano S.

Curr Med Chem. 2017 May 31;24(11):1066-1138. doi: 10.2174/0929867323666161227094049. Review.

PMID:
28025938
5.

A decade of targets and patented drugs for chemotherapy of Chagas disease.

Duschak VG.

Recent Pat Antiinfect Drug Discov. 2011 Sep 1;6(3):216-59. Review.

PMID:
21824073
6.

Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution.

Rivarola HW, Paglini-Oliva PA.

Curr Drug Targets Cardiovasc Haematol Disord. 2002 Jun;2(1):43-52. Review.

PMID:
12769656
7.

Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning.

Alberca LN, Sbaraglini ML, Balcazar D, Fraccaroli L, Carrillo C, Medeiros A, Benitez D, Comini M, Talevi A.

J Comput Aided Mol Des. 2016 Apr;30(4):305-21. doi: 10.1007/s10822-016-9903-6. Epub 2016 Feb 18.

PMID:
26891837
8.

[The chemotherapy of Chagas disease].

Stoppani AO.

Medicina (B Aires). 1999;59 Suppl 2:147-65. Review. Spanish.

PMID:
10668258
9.

Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.

Urbina JA.

Acta Trop. 2010 Jul-Aug;115(1-2):55-68. doi: 10.1016/j.actatropica.2009.10.023. Epub 2009 Nov 10. Review.

PMID:
19900395
10.

An insight on targets and patented drugs for chemotherapy of Chagas disease.

Duschak VG, Couto AS.

Recent Pat Antiinfect Drug Discov. 2007 Jan;2(1):19-51. Review.

PMID:
18221162
11.

Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.

Vázquez K, Paulino M, Salas CO, Zarate-Ramos JJ, Vera B, Rivera G.

Mini Rev Med Chem. 2017;17(11):939-946. doi: 10.2174/1389557517666170315145410. Review.

PMID:
28302040
12.

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.

Moraes CB, Giardini MA, Kim H, Franco CH, Araujo-Junior AM, Schenkman S, Chatelain E, Freitas-Junior LH.

Sci Rep. 2014 Apr 16;4:4703. doi: 10.1038/srep04703.

13.

4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.

Calvet CM, Choi JY, Thomas D, Suzuki B, Hirata K, Lostracco-Johnson S, de Mesquita LB, Nogueira A, Meuser-Batista M, Silva TA, Siqueira-Neto JL, Roush WR, de Souza Pereira MC, McKerrow JH, Podust LM.

PLoS Negl Trop Dis. 2017 Dec 27;11(12):e0006132. doi: 10.1371/journal.pntd.0006132. eCollection 2017 Dec.

14.

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease.

Assíria Fontes Martins T, de Figueiredo Diniz L, Mazzeti AL, da Silva do Nascimento ÁF, Caldas S, Caldas IS, de Andrade IM, Ribeiro I, Bahia MT.

PLoS One. 2015 Jun 15;10(6):e0128707. doi: 10.1371/journal.pone.0128707. eCollection 2015.

15.

Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.

Hartmann AP, de Carvalho MR, Bernardes LSC, Moraes MH, de Melo EB, Lopes CD, Steindel M, da Silva JS, Carvalho I.

Eur J Med Chem. 2017 Nov 10;140:187-199. doi: 10.1016/j.ejmech.2017.08.064. Epub 2017 Sep 4.

PMID:
28926763
16.

Bioactive lipids in Trypanosoma cruzi infection.

Machado FS, Mukherjee S, Weiss LM, Tanowitz HB, Ashton AW.

Adv Parasitol. 2011;76:1-31. doi: 10.1016/B978-0-12-385895-5.00001-3. Review.

17.

Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.

Ferreira de Almeida Fiuza L, Peres RB, Simões-Silva MR, da Silva PB, Batista DDGJ, da Silva CF, Nefertiti Silva da Gama A, Krishna Reddy TR, Soeiro MNC.

Eur J Med Chem. 2018 Apr 10;149:257-268. doi: 10.1016/j.ejmech.2018.02.020. Epub 2018 Feb 23.

PMID:
29501946
18.

Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease.

García MC, Ponce NE, Sanmarco LM, Manzo RH, Jimenez-Kairuz AF, Aoki MP.

Antimicrob Agents Chemother. 2016 May 23;60(6):3700-8. doi: 10.1128/AAC.00404-16. Print 2016 Jun.

19.

Therapeutical approaches under investigation for treatment of Chagas disease.

Bahia MT, Diniz Lde F, Mosqueira VC.

Expert Opin Investig Drugs. 2014 Sep;23(9):1225-37. doi: 10.1517/13543784.2014.922952. Epub 2014 May 26. Review.

PMID:
24855989
20.

Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.

Benaim G, Sanders JM, Garcia-Marchán Y, Colina C, Lira R, Caldera AR, Payares G, Sanoja C, Burgos JM, Leon-Rossell A, Concepcion JL, Schijman AG, Levin M, Oldfield E, Urbina JA.

J Med Chem. 2006 Feb 9;49(3):892-9.

PMID:
16451055

Supplemental Content

Support Center